
From: Michael Perfetto
To: Michael Clarke; Doug Boothe
Sent: 9/13/2012 7:31:56 PM
Subject: RE: DEA meeting

Thank you.

I look forward to discussing this with you.

Take care.

-----Original Message-----

From: Michael Clarke
Sent: Thursday, September 13, 2012 2:44 PM
To: Doug Boothe; Michael Perfetto
Subject: RE: DEA meeting

Doug,

I just left you a voicemail with some detail, but we should talk.

The DEA meeting was essentially a lecture on the status of where our oxycodone pills are ending up in Florida, using market data and DEA license numbers to track our product to specific Florida towns and pharmacies in 2010, 2011 and 2012. They spent about 90 minutes and 100 slides walking us through the number of pills dispensed in FL, compared to some other states and the national averages to make the case that a significant number of high volume of scripts in FL must be directed towards inappropriate uses, either through bad doctors, shady pharmacies or both. They are challenging all manufacturers and distributors to put controls in place to handle the potential diversion of oxycodone. Walgreens and Happy Harry were pharmacies with particularly high numbers of oxy scripts in remote sections of Florida.

Michael

Michael R. Clarke
Actavis
973-889-6667
MCLARKE@actavis.com

-----Original Message-----


From: Doug Boothe
Sent: Thursday, September 13, 2012 2:23 PM
To: Michael Perfetto; Michael Clarke
Subject: DEA meeting

What exactly was covered yesterday?

I got a request from Bob Stewart (Watson) and he indicated that it was a very tough meeting and something about Walgreens.

Did I miss something?

DB
Doug Boothe
CEO, Actavis Inc.
973-889-6633 (office)



ACTAVIS0238164

P-02480_00001